Press Releases

New Patent for Adipose Stem Cells Issued to VetStem

2017-09-12 --

VetStem Biopharma, Inc., announced that a major new European patent has been granted to the University of Pittsburgh and VetStem has full license to that patent. This patent covers methods for isolating stem cells from adipose tissue, the composition of the adipose-derived stem cell itself, combining this stem cell with matrix materials, and incorporating the stem cells in an implant. This patent will provide coverage for the on-going commercial and development programs at VetStem and may be available for licensing to other companies interested in working in this field.

This new patent adds to the other patents in the VetStem portfolio that cover methods of using regenerative cells from adipose tissue for the eye, pancreas, liver, bone and muscle. VetStem has exclusive worldwide rights for veterinary use of these other licensed patents and this strengthens further the company’s intellectual property position in this rapidly developing field.

As the first company in the United States to offer fat derived stem cell services for veterinary use, VetStem has rapidly developed the market, providing treatments to over 13,000 horses, dogs, cats and exotic species. “Intellectual property rights are critical and can be confusing in a rapidly developing market with evolving technology.” said Bob Harman, DVM, MPVM, CEO of VetStem. “We have taken appropriate actions to protect the market that we are creating in regenerative veterinary medicine and to ensure that the value of the company is optimized. The value of this technology has increased greatly since the founding of the company in 2002 as the business model has evolved and many companies and Universities worldwide have validated the therapeutic activity of these cells.”